RIGL : Summary for Rigel Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Rigel Pharmaceuticals, Inc. (RIGL)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.52+0.22 (+9.57%)
At close: 4:00PM EST
People also watch
ARRYPGNXPTIESPPINBIX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.30
Open2.31
Bid2.41 x 2500
Ask2.92 x 2000
Day's Range2.29 - 2.53
52 Week Range1.88 - 4.38
Volume1,893,944
Avg. Volume782,077
Market Cap299.65M
Beta1.27
PE Ratio (TTM)-3.49
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Cheap Healthcare Stocks You Can Buy Right Now
    Motley Fool3 days ago

    3 Cheap Healthcare Stocks You Can Buy Right Now

    If you're on the hunt for great healthcare stocks trading at a discount, these three deserve some attention.

  • PR Newswire24 days ago

    Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

    SOUTH SAN FRANCISCO, Calif., Feb. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the closing of its previously announced underwritten public offering of 23,000,000 shares ...

  • PR Newswire27 days ago

    Rigel Announces Pricing Of Public Offering Of Common Stock

    Jefferies LLC, Piper Jaffray & Co. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.  H.C. Wainwright & Co., LLC is acting as Lead Manager for the offering. A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov.  When available, copies of the final prospectus supplement may also be obtained from the offices of Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com, from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com, or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 25th Floor, New York, NY 10036, or by telephone at (800) 414-3627 or by email at bmoprospectus@bmo.com.